AstraZeneca reports mixed Q4 earnings; issues FY23 soft guidance
AstraZeneca press release (NASDAQ:AZN): Q4 Non-GAAP EPS of $1.38 beats by $0.05.
Revenue of $11.21B (-6.7% Y/Y)  misses by $80M.
Total Revenue in the fourth quarter was impacted by the decline in Vaxzevria. Excluding Vaxzevria, Total Revenue in the quarter increased 17%.
Core Gross Margin of 77% in the fourth quarter was impacted by inventory write downs and manufacturing termination fees for Evusheld.

FY 2023 Guidance summary (Growth numbers at CER) â Total Revenue is expected to increase by a low-to-mid single-digit percentage; Total Revenue excluding COVID-19 medicines 8 is expected to increase by a low double-digit percentage; Core EPS is expected to increase by a high single-digit to low double-digit percentage.